Assignee
OREXO AB
SE·32 granted patents·24 pending applications·150 citations·filing 2000–2025
Top patents by PatentIndex Score
56 records- 0197US10729687B1Pharmaceutical composition for nasal deliveryOREXO AB·Filed 2020·Granted Aug 4, 2020·11 cites·17 claims
- 0297US10653690B1Pharmaceutical composition for nasal deliveryOREXO AB·Filed 2019·Granted May 19, 2020·31 cites·17 claims
- 0396US12268684B2Pharmaceutical composition for nasal deliveryOREXO AB·Filed 2023·Granted Apr 8, 2025·3 cites·35 claims
- 0496US11737980B2Pharmaceutical composition for drug deliveryOREXO AB·Filed 2021·Granted Aug 29, 2023·5 cites·21 claims
- 0596US10898480B1Pharmaceutical composition for nasal deliveryOREXO AB·Filed 2020·Granted Jan 26, 2021·7 cites·15 claims
- 0695US11957647B2Pharmaceutical composition comprising adrenalineOREXO AB·Filed 2023·Granted Apr 16, 2024·5 cites·30 claims
- 0794US12303472B2Pharmaceutical device for use in intranasal administrationOREXO AB·Filed 2023·Granted May 20, 2025·3 cites·30 claims
- 0893US8658198B2Non-abusable pharmaceutical composition comprising opioidsOREXO AB·Filed 2013·Granted Feb 25, 2014·15 cites·33 claims
- 0992US10874661B2Abuse-resistant pharmaceutical composition for the treatment of opioid dependenceOREXO AB·Filed 2018·Granted Dec 29, 2020·2 cites·19 claims
- 1091US11617746B1Method of controlling depression in subjects treated for opioid dependenceOREXO AB·Filed 2021·Granted Apr 4, 2023·2 cites·24 claims
- 1191US2026041682A1Pharmaceutical composition for nasal deliveryOREXO AB·Filed 2025·Application pending·0 cites
- 1290US9259421B2Abuse-resistant pharmaceutical composition for the treatment of opioid dependenceOREXO AB·Filed 2015·Granted Feb 16, 2016·5 cites·24 claims
- 1390US2024390361A1New abuse-resistant pharmaceutical composition for the treatment of opioid dependenceOREXO AB·Filed 2023·Application pending·0 cites
- 1489US9439900B2Abuse-resistant pharmaceutical composition for the treatment of opioid dependenceOREXO AB·Filed 2014·Granted Sep 13, 2016·5 cites·18 claims
- 1589US8980305B2Non-abusable pharmaceutical composition comprising opioidsOREXO AB·Filed 2013·Granted Mar 17, 2015·9 cites·35 claims
- 1688US8940330B2Abuse-resistant pharmaceutical composition for the treatment of opioid dependenceOREXO AB·Filed 2012·Granted Jan 27, 2015·5 cites·11 claims
- 1786US11986472B1Method of controlling alcohol consumption in subjects treated for opioid dependenceOREXO AB·Filed 2021·Granted May 21, 2024·1 cites·8 claims
- 1886US8815911B2Alfentanil composition for the treatment of acute painOREXO AB·Filed 2013·Granted Aug 26, 2014·11 cites·19 claims
- 1983US7785626B2Gastric acid secretion inhibiting compositionOREXO AB·Filed 2003·Granted Aug 31, 2010·18 cites·31 claims
- 2082US7910132B2Pharmaceutical composition for the treatment of acute disordersOREXO AB·Filed 2006·Granted Mar 22, 2011·3 cites·11 claims
- 2178US12472154B2Pharmaceutical composition comprising adrenalineOREXO AB·Filed 2024·Granted Nov 18, 2025·0 cites·31 claims
- 2278US11020387B2Abuse-resistant pharmaceutical composition for the treatment of opioid dependenceOREXO AB·Filed 2020·Granted Jun 1, 2021·0 cites·14 claims
- 2378US10946010B2Abuse-resistant pharmaceutical composition for the treatment of opioid dependenceOREXO AB·Filed 2020·Granted Mar 16, 2021·0 cites·21 claims
- 2478US2025205224A1Pharmaceutical composition for nasal deliveryOREXO AB·Filed 2025·Application pending·0 cites
- 2577US11433066B2Abuse-resistant pharmaceutical composition for the treatment of opioid dependenceOREXO AB·Filed 2020·Granted Sep 6, 2022·0 cites·11 claims
- 2677US11020388B2Abuse-resistant pharmaceutical composition for the treatment of opioid dependenceOREXO AB·Filed 2020·Granted Jun 1, 2021·0 cites·21 claims
- 2776US12138259B1Method of controlling depression in subjects treated for opioid dependenceOREXO AB·Filed 2023·Granted Nov 12, 2024·0 cites·22 claims
- 2876US11883392B2Pharmaceutical composition for nasal deliveryOREXO AB·Filed 2021·Granted Jan 30, 2024·0 cites·35 claims
- 2975US12357573B2Pharmaceutical composition for drug deliveryOREXO AB·Filed 2023·Granted Jul 15, 2025·0 cites·54 claims
- 3075US7815940B2Gastric acid secretion inhibiting compositionOREXO AB·Filed 2002·Granted Oct 19, 2010·6 cites·12 claims
- 3174US9345698B2Alfentanil composition for the treatment of acute painOREXO AB·Filed 2014·Granted May 24, 2016·2 cites·24 claims
- 3268US2018042920A1New abuse-resistant pharmaceutical composition for the treatment of opioid dependenceOREXO AB·Filed 2017·Application pending·0 cites
- 3368US2018104235A1New abuse-resistant pharmaceutical composition for the treatment of opioid dependenceOREXO AB·Filed 2017·Application pending·0 cites
- 3467US2017246161A1Abuse-resistant pharmaceutical composition for the treatment of opioid dependenceOREXO AB·Filed 2016·Application pending·0 cites
- 3566US2025262174A1New pharmaceutical device for use in intranasal administrationOREXO AB·Filed 2025·Application pending·0 cites
- 3666US2014023704A1New abuse-resistant pharmaceutical composition for the treatment of opioid dependenceOREXO AB·Filed 2013·Application pending·0 cites
- 3766US2008286368A1Pharmaceutical composition for the treatment of acute disordersOREXO AB·Filed 2008·Application pending·0 cites
- 3866US2016375010A1Abuse-resistant pharmaceutical composition for the treatment of opioid dependenceOREXO AB·Filed 2016·Application pending·0 cites
- 3963US2014030336A1Pharmaceutical composition for the treatment of acute disordersOREXO AB·Filed 2013·Application pending·0 cites
- 4063US2014335190A1New non-abusable pharmaceutical composition comprising opioidsOREXO AB·Filed 2014·Application pending·0 cites
- 4162US2024408212A1Pharmaceutical composition comprising biopharmaceutical drug compoundsOREXO AB·Filed 2022·Application pending·0 cites
- 4262US2015238482A1New abuse-resistant pharmaceutical composition for the treatment of opioid dependenceOREXO AB·Filed 2015·Application pending·0 cites
- 4362US2013195976A1Pharmaceutical composition for the treatment of acute disordersOREXO AB·Filed 2013·Application pending·0 cites
- 4459US2008031941A1Gastric acid secretion inhibiting compositionOREXO AB·Filed 2007·Application pending·0 cites
- 4558US9597281B2Pharmaceutical formulations useful in the treatment of insomniaOREXO AB·Filed 2013·Granted Mar 21, 2017·0 cites·26 claims
- 4658US7771747B2Gastric acid secretion inhibiting compositionOREXO AB·Filed 2006·Granted Aug 10, 2010·0 cites·21 claims
- 4756US2013017263A1Gastric acid secretion inhibiting compositionOREXO AB·Filed 2012·Application pending·0 cites
- 4855US9782396B2Alfentanil composition for the treatment of acute painOREXO AB·Filed 2016·Granted Oct 10, 2017·0 cites·22 claims
- 4954US2018214437A1New alfentanil composition for the treatment of acute painOREXO AB·Filed 2017·Application pending·0 cites
- 5054US2016151351A1Non-abusable pharmaceutical composition comprising opioidsOREXO AB·Filed 2015·Application pending·0 cites
Showing the top 50 of 56 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →